Home LiteratureArticle Details
PMID: 18422469 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Pharmacogenetics: potential role in the treatment of diabetes and obesity.

Expert opinion on pharmacotherapy ·Vol. 9 ·No. 7 ·2008-05-00 ·Pages 1109-19

Vella A, Camilleri M

Abstract

Common genetic variation is associated with increased risk of common metabolic diseases such as type 1 and type 2 diabetes, and obesity. Increasing experience with genetic association studies has led to an understanding of the large sample sizes required to detect a weak to moderate genetic predisposition to disease, the need to reproduce such associations in independent cohorts, and the statistical criteria required to detect a true association. This approach has been used successfully to identify disease-associated gene variation usually in representative populations of large numbers. To review the current understanding of how common genetic variation influences predisposition to, and treatment of, metabolic disease. Review of scientific literature. While there has been progress in understanding how genetic variation predisposes to diabetes and obesity, and how candidate genes may alter drug response, several caveats limit the interpretation and significance of pharmacogenetic studies published to date: those caveats typically include relatively small numbers of participants and choice of endpoints in determining gene-associated differences in response, which may not be clinically significant or relevant as a biomarker or predictor of a desired clinical effect. The genetic variants studied at a given locus are often limited in number and may not represent a comprehensive map of the region under study. The pharmacogenetic associations in diabetes and obesity that have been reported to date have had limited impact on the choice of individual treatments. We perceive, however, that this field is in its infancy in these multifactorial metabolic diseases, and with further advances and future drug intervention trials designed in a way that allows a more clear interpretation of the impact of genetic variation on differences in drug response in obesity and diabetes, it is anticipated that pharmacogenetics will have a significant impact on individualizing medical care.

MeSH Terms
Biomarkers Controlled Clinical Trials as Topic Diabetes Mellitus, Type 1/drug therapy,genetics Diabetes Mellitus, Type 2/drug therapy,genetics Genetic Predisposition to Disease Humans Obesity/drug therapy,genetics Pharmacogenetics
Chemicals
Biomarkers
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Vella Adrian
Mayo Clinic, Division of Endocrinology and Metabolism, Department of Medicine, 200, First ST SW, Rochester, MN 55905, USA.
Camilleri Michael
References (82)
82 references, click to expand
  1. The glucagon-like peptides.
    Endocr Rev. 1999 Dec;20(6):876-913 PMID: 10605628
  2. IL2RA/CD25 polymorphisms contribute to multiple sclerosis susceptibility.
    J Neurol. 2007 May;254(5):682-4 PMID: 17420929
  3. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program.
    Diabetes. 2007 Feb;56(2):531-6 PMID: 17259403
  4. Genome-wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: lessons for study design.
    Inflamm Bowel Dis. 2007 Dec;13(12):1554-60 PMID: 17712840
  5. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.
    Regul Pept. 2005 Aug 15;130(1-2):1-6 PMID: 15975668
  6. A genome-wide association study identifies novel risk loci for type 2 diabetes.
    Nature. 2007 Feb 22;445(7130):881-5 PMID: 17293876
  7. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.
    Mol Cell Biol. 2001 Aug;21(16):5471-7 PMID: 11463829
  8. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.
    Nat Genet. 2004 Apr;36(4):337-8 PMID: 15004560
  9. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
    J Clin Invest. 2007 May;117(5):1422-31 PMID: 17476361
  10. Common variants in WFS1 confer risk of type 2 diabetes.
    Nat Genet. 2007 Aug;39(8):951-3 PMID: 17603484
  11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
    N Engl J Med. 1993 Sep 30;329(14):977-86 PMID: 8366922
  12. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.
    Diabetes. 2007 May;56(5):1475-80 PMID: 17303799
  13. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes.
    Diabetes. 2007 Mar;56(3):685-93 PMID: 17327436
  14. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
    J Clin Endocrinol Metab. 2007 Apr;92(4):1502-9 PMID: 17213274
  15. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.
    Science. 1996 Nov 29;274(5292):1527-31 PMID: 8929413
  16. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits.
    PLoS Genet. 2007 Jul;3(7):e115 PMID: 17658951
  17. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.
    Nat Rev Drug Discov. 2007 Nov;6(11):904-16 PMID: 17971785
  18. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism.
    Pharmacogenetics. 2003 Aug;13(8):453-9 PMID: 12893983
  19. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Diabetes. 1998 Mar;47(3):345-51 PMID: 9519738
  20. Statistical false positive or true disease pathway?
    Nat Genet. 2006 Jul;38(7):731-3 PMID: 16804532
  21. Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism.
    J Lipid Res. 2007 Jul;48(7):1433-44 PMID: 17374881
  22. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.
    Science. 2007 May 11;316(5826):889-94 PMID: 17434869
  23. Sequence variation in PPARG may underlie differential response to troglitazone.
    Diabetes. 2005 Nov;54(11):3319-25 PMID: 16249460
  24. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.
    Science. 2007 Jun 1;316(5829):1341-5 PMID: 17463248
  25. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
    Nature. 2003 May 29;423(6939):506-11 PMID: 12724780
  26. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution.
    Nat Genet. 2007 Feb;39(2):218-25 PMID: 17206141
  27. Genetic prediction of future type 2 diabetes.
    PLoS Med. 2005 Nov 1;2(12):e345 PMID: 17570749
  28. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet. 1998 Sep 12;352(9131):837-53 PMID: 9742976
  29. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes.
    Endocrinology. 2006 Jun;147(6):2657-63 PMID: 16556760
  30. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.
    Nat Genet. 2007 Sep;39(9):1074-82 PMID: 17676041
  31. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance.
    Diabetes. 2006 Sep;55(9):2654-9 PMID: 16936218
  32. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders.
    Gut. 2004 Jun;53(6):829-37 PMID: 15138209
  33. Effects of recombinant leptin therapy in a child with congenital leptin deficiency.
    N Engl J Med. 1999 Sep 16;341(12):879-84 PMID: 10486419
  34. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Clin Gastroenterol Hepatol. 2007 Jul;5(7):829-37 PMID: 17544870
  35. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present.
    Pharmacoepidemiol Drug Saf. 2007 Feb;16(2):132-43 PMID: 17072896
  36. The efficacy and safety of sibutramine for weight loss: a systematic review.
    Arch Intern Med. 2004 May 10;164(9):994-1003 PMID: 15136309
  37. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?
    Endocr Rev. 2005 Dec;26(7):898-915 PMID: 16126938
  38. Long-term weight control study: conclusions.
    Clin Pharmacol Ther. 1992 May;51(5):642-6 PMID: 1587079
  39. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.
    Clin Med Res. 2005 Nov;3(4):207-13 PMID: 16303885
  40. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.
    JAMA. 1999 Oct 27;282(16):1568-75 PMID: 10546697
  41. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
    Diabetes Care. 2003 Mar;26(3):825-31 PMID: 12610044
  42. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.
    N Engl J Med. 2006 Jul 20;355(3):241-50 PMID: 16855264
  43. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
    Nat Genet. 2007 Aug;39(8):977-83 PMID: 17603485
  44. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
    Neurogastroenterol Motil. 2007 Aug;19 Suppl 2:40-5 PMID: 17620087
  45. Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy.
    Pharmacogenomics J. 2003;3(5):284-96 PMID: 14583798
  46. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.
    J Pharmacol Exp Ther. 2002 Aug;302(2):510-5 PMID: 12130709
  47. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
    Curr Pharm Des. 2001 Sep;7(14):1399-412 PMID: 11472275
  48. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet. 1998 Sep 12;352(9131):854-65 PMID: 9742977
  49. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.
    J Clin Invest. 2007 Aug;117(8):2155-63 PMID: 17671651
  50. Phenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese women.
    Obes Res. 2003 Mar;11(3):415-9 PMID: 12634439
  51. Molecular genetics goes to the diabetes clinic.
    Clin Med (Lond). 2005 Sep-Oct;5(5):476-81 PMID: 16268330
  52. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.
    Science. 2007 Jun 1;316(5829):1331-6 PMID: 17463246
  53. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.
    Nat Genet. 2006 Mar;38(3):320-3 PMID: 16415884
  54. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals.
    Diabetes. 2006 Oct;55(10):2890-5 PMID: 17003358
  55. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
    Diabetes Care. 2004 Jun;27(6):1365-8 PMID: 15161789
  56. Genome-wide association studies for common diseases and complex traits.
    Nat Rev Genet. 2005 Feb;6(2):95-108 PMID: 15716906
  57. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.
    Diabetes. 2003 Feb;52(2):568-72 PMID: 12540637
  58. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
    Diabetes Care. 2005 May;28(5):1092-100 PMID: 15855572
  59. Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women.
    J Mol Med (Berl). 2006 Dec;84(12):1005-14 PMID: 17665514
  60. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
    Diabetes. 2005 Aug;54(8):2460-70 PMID: 16046315
  61. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    N Engl J Med. 2005 Nov 17;353(20):2121-34 PMID: 16291982
  62. Variation in FTO contributes to childhood obesity and severe adult obesity.
    Nat Genet. 2007 Jun;39(6):724-6 PMID: 17496892
  63. Genetic determinants of statin intolerance.
    Lipids Health Dis. 2007 Mar 21;6:7 PMID: 17376224
  64. Genetics of obesity in humans.
    Endocr Rev. 2006 Dec;27(7):710-18 PMID: 17122358
  65. Cellular mechanism of action of metformin.
    Diabetes Care. 1990 Jun;13(6):696-704 PMID: 2162756
  66. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.
    Ann Intern Med. 2000 Aug 15;133(4):263-74 PMID: 10929166
  67. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).
    Diabet Med. 2001 Mar;18(3):206-12 PMID: 11318841
  68. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    N Engl J Med. 2006 Aug 3;355(5):467-77 PMID: 16885550
  69. Characterization and significance of sulfonylurea receptors.
    Diabetes Care. 1990 Aug;13 Suppl 3:2-8 PMID: 2209340
  70. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.
    Nat Genet. 2000 Sep;26(1):76-80 PMID: 10973253
  71. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program.
    Diabetologia. 2008 Mar;51(3):451-7 PMID: 18060660
  72. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    J Clin Endocrinol Metab. 2006 Jun;91(6):2334-9 PMID: 16595597
  73. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.
    Nat Genet. 2007 Jul;39(7):857-64 PMID: 17554260
  74. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
    Diabetes Obes Metab. 2005 Nov;7(6):692-8 PMID: 16219012
  75. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta.
    J Biol Chem. 2005 Jan 14;280(2):1457-64 PMID: 15525634
  76. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med. 1998 Feb 1;128(3):165-75 PMID: 9454524
  77. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men.
    J Clin Endocrinol Metab. 2000 Nov;85(11):4003-9 PMID: 11095423
  78. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.
    Nat Genet. 2007 Jun;39(6):770-5 PMID: 17460697
  79. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms.
    Am J Hum Genet. 2005 May;76(5):773-9 PMID: 15776395
  80. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
    Science. 2005 Dec 9;310(5754):1642-6 PMID: 16308421
  81. Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes.
    J Clin Endocrinol Metab. 2005 Jun;90(6):3629-37 PMID: 15797964
  82. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.
    Science. 2007 Jun 1;316(5829):1336-41 PMID: 17463249
Article Info
Journal
Expert opinion on pharmacotherapy
Abbr.
Expert Opin Pharmacother
ISSN
1744-7666
DOI
10.1517/14656566.9.7.1109
Published
2008-05-00
Pages
1109-19
Language
English
Region
England
NLM ID
100897346
PMCID
PMC3901565
Subset
IM
Grants
NIDDK NIH HHS · R01 DK078646 · United States
NIDDK NIH HHS · P01 DK068055 · United States
NIDDK NIH HHS · P01-DK068055 · United States
NCRR NIH HHS · RR024150 · United States
NIDDK NIH HHS · DK02638 · United States
NIDDK NIH HHS · DK67071 · United States
External Links
PubMed source DOI: 10.1517/14656566.9.7.1109 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2